Edesa Biotech (EDSA) has released an update.
Edesa Biotech’s novel drug, paridiprubart, has been selected by the U.S. Biomedical Advanced Research and Development Authority (BARDA) for a Phase 2 trial in patients with acute respiratory distress syndrome (ARDS) from various causes. The drug aims to modulate the immune system’s response to public health threats and has shown promise in reducing mortality in ARDS patients during a previous study. This effort is part of a broader public-private initiative to develop therapeutics that are ready for rapid deployment in emergencies, including pandemics and biodefense situations.
For further insights into EDSA stock, check out TipRanks’ Stock Analysis page.
